welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Sodium Nitrate to Improve Blood Flow
study id #: NCT02847975
condition: Becker Muscular Dystrophy
Investigators recently showed that tadalafil restores functional sympatholysis in patients with Becker muscular dystrophy (BMD). If tadalafil restores functional sympatholysis in BMD via the NO-cyclic guanosine monophosphate pathway, then functional sympatholysis should also be restored by sodium nitrite— which is an indirect nitric oxide donor.
intervention: Sodium nitrate
mechanism of action: Nitrate supplement to alter funcitonal muslce ischaemia
last updated: November 21, 2018
start date: October 2013
estimated completion: December 2014
phase of development: Phase 1
size / enrollment: 11
- change in muscle tissue oxygenation [ Time Frame: change from baseline to post treatment (3-4 hours) ]
The pre-specified primary outcome is the pre vs. post treatment change in functional sympatholysis measured by muscle oxygenation.
• Becker muscular dystrophy
• age 15-55 years of age
• hypertension, diabetes, or heart failure by standard clinical criteria
• elevated brain natriuretic peptide level (>100 pg/ml)
• Left ventricular ejection fraction < 50%
• cardiac rhythm disorder, specifically: rhythm other than sinus, supraventricular tachycardia, atrial fibrillation, ventricular tachycardia, heart block
• continuous ventilatory support
• liver disease
• renal impairment
• history of asthma or bronchospasm
• use of any medications other than common supplements
• unable to perform handgrip exercise
Safety Study of Flavocoxid in Duchenne Muscular DystrophyObjective of this study is to evaluate s...
Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (D...This research study is designed to evalu...
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular DystrophyThis is a Phase 1, double-blind, placebo...
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of the study is to see wheth...
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
Nutrition Considerations in Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a s...
Dietary supplement increases muscle force by 50% in the Duchenne muscular dystrophy mouse modelDuchenne muscular dystrophy (DMD) is a h...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dy...Background: Edasalonexent is an orally ...
Bone health in a cohort of Irish Duchenne muscular dystrophy patientsIntroduction: Reduced mobility in Duche...